Alpha 2.0
Login Register
» Authors » Amanda Baines

Amanda Baines

Explore the profile of Amanda Baines including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 49
Followers 0
Related Specialties
Pulmonary Medicine
Oncology
Pharmacology
Top 10 Co-Authors
Jackie Moynihan
Stephanie Gaillard
Richard Beasley
Peter Daley-Yates
Mathew Williams
Vivek Samnotra
James Fingleton
Rodger Kempsford
George Bardsley
Irene Braithwaite
Published In
Respir Res
J Aerosol Med Pulm Drug Deliv
Gynecol Oncol
Respir Med
JCO Precis Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial
Liu J, Gaillard S, Wahner Hendrickson A, Yeku O, Diver E, Gunderson Jackson C, et al.
JCO Precis Oncol . 2024 May; 8:e2300693. PMID: 38754056
Purpose: To report the results of OPAL (ClinicalTrials.gov identifier: NCT03574779) cohort A, a single-arm substudy of niraparib plus dostarlimab and bevacizumab for the treatment of advanced, platinum-resistant ovarian cancer (PROC)....
2.
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)
Randall L, OMalley D, Monk B, Coleman R, Gaillard S, Adams S, et al.
Gynecol Oncol . 2023 Oct; 178:161-169. PMID: 37890345
Objective: This study assessed the efficacy, safety, and health-related quality of life (HRQoL) of the treatment regimen of dostarlimab, a programmed death-1 inhibitor, combined with niraparib, a poly (ADP-ribose) polymerase...
3.
Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial
Daley-Yates P, Keppler B, Baines A, Bardsley G, Fingleton J
Respir Res . 2022 Sep; 23(1):258. PMID: 36127726
Background: Fluticasone furoate/vilanterol trifenatate (FF/VI) is an inhaled therapy for the treatment of asthma, with a prolonged duration of anti-inflammatory and bronchodilatory action. This study investigated the global metabolomic and...
4.
Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial
Bardsley G, Daley-Yates P, Baines A, Kempsford R, Williams M, Mallon T, et al.
Respir Res . 2018 Jul; 19(1):133. PMID: 30001712
Background: Fluticasone furoate/Vilanterol trifenatate (FF/VI) is an inhaled corticosteroid/long-acting beta-agonist combination with a prolonged bronchodilator duration of action. We characterised the time-course of onset and offset of airway anti-inflammatory action...
5.
Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma
Braithwaite I, Williams M, Power S, Pilcher J, Weatherall M, Baines A, et al.
Respir Med . 2016 Oct; 119:115-121. PMID: 27692131
Background: Fluticasone furoate (FF)/vilanterol (VI) is a once-daily maintenance treatment for asthma and chronic obstructive pulmonary disease. The duration of bronchodilation beyond 24 h has not been determined previously. Methods:...
6.
Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler
Prime D, De Backer W, Hamilton M, Cahn A, Preece A, Kelleher D, et al.
J Aerosol Med Pulm Drug Deliv . 2015 Sep; 28(6):486-97. PMID: 26372467
Background: Two studies were undertaken to characterize the maximal effort inhalation profiles of healthy subjects and patients with asthma or chronic obstructive pulmonary disease (COPD) through a moderate-resistance dry powder...